Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20143210 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB | |
| SCHEMBL3231146 | 0.95 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB | |
| SCHEMBL7278054 | 0.95 | NR1I2 (0.53) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB | |
| SCHEMBL15664773 | 0.95 | NR1I2 (0.53) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB | |
| SCHEMBL27522848 | 0.94 | BCHE (0.51) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB | |
| Hydrochloric Acid SCHEMBL27415879 | 0.93 | NR1I2 (0.52) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB | |
| Acetic Acid SCHEMBL27390252 | 0.90 | NR1I2 (0.50) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB | |
| SCHEMBL8958766 | 0.90 | BCHE (0.54) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB | |
| SCHEMBL1825154 | 0.90 | BCHE (0.54) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB | |
| SCHEMBL3969870 | 0.90 | LMNA (0.52) | SMN1; SMN2CYP3A4CYP2D6KCNH2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387307-A1 | METHOD OF TREATING DISEASE | CREWS THOMAS M (US) | 2022-12-08 | — | — | US | disclosed |
| US-9968589-B2 | Method of treating disease by auricular anesthesia of cranial nerves | CREWS THOMAS M (US) | 2018-05-15 | — | — | US | disclosed |
| EP-0749421-A1 | SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 1996-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387307-A1 | METHOD OF TREATING DISEASE | COXFA4L2, ASAH2, OTC | SMN1; SMN2 1007/4885CYP3A4 4667/4885CYP2D6 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.